本组肝癌病人移植术后3年无复发生存率为100 ％ 。
在治疗的第3年，雌激素受体阳性患者获得97%的无远处复发生存率，绝对危险度大幅下降11%。
At 3 years, ER-positive patients achieved a DRFS of 97% and a significant absolute risk reduction of 11%.
对于这些患者，辅助盆腔放疗具有明显的益处，和那些没有进一步治疗的病例比，能极大的改善复发生存率。
For these patients, adjuvant pelvic radiation therapy provides clear therapeutic benefit, with significantly improved relapse-free survival rates when compared with those who had no further therapy.
研究者同时发现有28%的患者被预测为对治疗敏感，他们的3年无远处复发生存率为92%，绝对危险度大幅下降18%。
They also observed that in 28% of patients predicted to be sensitive to treatment, 3-year distant relapse-free survival (DRFS) was 92%, with a significant absolute risk reduction of 18%.
结论选择性肺动脉灌注化疗用于肺叶切除术后的肺癌患者，能够杀灭和抑制局部微转移灶，减少局部复发和远期血行转移的发生率，提高长期生存率。
Conclusion Pulmonary artery infusion for lung cancer patients after lobectomy can reduce the post operative recurrence and metastasis and improve the long term survival rates.
结论选择性肺动脉灌注化疗用于肺叶切除术后的肺癌患者，能够杀灭和抑制局部微转移灶，减少局部复发和远期血行转移的发生率，提高长期生存率。
Conclusion Pulmonary artery infusion for lung cancer patients after lobectomy can reduce the post operative recurrence and metastasis and improve the long term survival rates.
应用推荐